Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


I-SPY 2 Helping To Normalize Adaptive Trial Designs

Executive Summary

Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.


Related Content

Precision Medicine: Despite Gains, Optimum Use Far From Reached
Merck's Keytruda Offers Hope And Risk In Early Breast Cancer
Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening
AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA
FDA Encourages Pediatric Master Protocols With Bayesian Approach
Sky's The Limit On Savings For New NIH-Funded Innovative Trials Center
Rethinking Oncology Development: Master Protocols May Shorten Time To Approval
Tissue-Agnostic Approach To Cancer Drug Development Takes A Hit
Plexxikon's PLX3397 selected for I-SPY 2 breast cancer trial
Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s Perjeta


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts